1. Home
  2. CALT

CALT

Calliditas Therapeutics AB

Logo Calliditas Therapeutics AB

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.

Founded: 2004 Country:
Sweden
Sweden
Employees: N/A City: N/A
Market Cap: 586.1M IPO Year: 2020
Target Price: $39.33 AVG Volume (30 days): 8.0K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.00 EPS Growth: N/A
52 Week Low/High: $15.25 - $29.30 Next Earning Date: 05-14-2024
Revenue: $105,877,808 Revenue Growth: 401.35%
Revenue Growth (this year): 47.22% Revenue Growth (next year): 69.12%

Share on Social Networks: